159 related articles for article (PubMed ID: 10560397)
21. A new approach to the treatment of malignant effusion.
Li DJ; Wang YR; Tan XY; Wang HZ; Yao XD; Ba DN
Chin Med J (Engl); 1990 Dec; 103(12):998-1002. PubMed ID: 2127253
[TBL] [Abstract][Full Text] [Related]
22. [Clinical evaluation of intrapleural or peritoneal repetitive administration of Lentinan and OK-432 for malignant effusion].
Kawaoka T; Yoshino S; Kondo H; Yamamoto K; Hazama S; Oka M
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1565-7. PubMed ID: 16315870
[TBL] [Abstract][Full Text] [Related]
23. Intrapleural cisplatin and OK432 therapy for malignant pleural effusion caused by non-small cell lung cancer.
Ishida A; Miyazawa T; Miyazu Y; Iwamoto Y; Zaima M; Kanoh K; Sumiyoshi H; Doi M
Respirology; 2006 Jan; 11(1):90-7. PubMed ID: 16423208
[TBL] [Abstract][Full Text] [Related]
24. [Intrapleural transfer of LAK cells combined with rIL-2 in the treatment of advanced lung cancer with malignant pleural effusion].
Li DJ
Zhonghua Zhong Liu Za Zhi; 1989 Jul; 11(4):294-6. PubMed ID: 2625114
[TBL] [Abstract][Full Text] [Related]
25. [Intrathoracic infusion with a combination of low-dose minocycline, OK-432 and cisplatin for malignant pleural effusion].
Ishimori S; Okada S; Yamagata S; Satoh S
Gan To Kagaku Ryoho; 2005 Mar; 32(3):345-9. PubMed ID: 15791817
[TBL] [Abstract][Full Text] [Related]
26. Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515.
Yoshida K; Sugiura T; Takifuji N; Kawahara M; Matsui K; Kudoh S; Takada M; Fukuoka M; Ariyoshi Y; Fukuda H; Saijo N
Lung Cancer; 2007 Dec; 58(3):362-8. PubMed ID: 17716779
[TBL] [Abstract][Full Text] [Related]
27. A study of the cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells.
Guo YS; Xing ZL
Chin Med J (Engl); 1994 Dec; 107(12):903-5. PubMed ID: 7882727
[TBL] [Abstract][Full Text] [Related]
28. [Adhesion therapy for malignant pleural effusion (intrapleural administration of OK-432 with minocycline)].
Tanaka A; Sato T
Nihon Kokyuki Gakkai Zasshi; 1999 Jul; 37(7):531-7. PubMed ID: 10481458
[TBL] [Abstract][Full Text] [Related]
29. Influence of lymphocytes in malignant pleural effusion on the therapeutic efficacy of intrapleural OK-432 in lung cancer patients.
Shimizu T; Takahashi N; Terakado M; Akusawa H; Tsujino I; Horie T
Intern Med; 2006; 45(11):715-20. PubMed ID: 16819251
[TBL] [Abstract][Full Text] [Related]
30. Pleural effusion in breast cancer: a review of the Nottingham experience.
Banerjee AK; Willetts I; Robertson JF; Blamey RW
Eur J Surg Oncol; 1994 Feb; 20(1):33-6. PubMed ID: 8131866
[TBL] [Abstract][Full Text] [Related]
31. [Extrapleural pneumonectomy after hyperthermo-chemotherapy for the lung cancer patients with malignant pleural effusion].
Suzuki K; Funai K; Shundo Y; Asano K; Takamochi K; Asai K; Kazui T; Miura K
Kyobu Geka; 2004 Oct; 57(11):1023-7. PubMed ID: 15510815
[TBL] [Abstract][Full Text] [Related]
32. Multivariate analysis of prognostic features in malignant pleural effusions from breast cancer patients.
Dieterich M; Goodman SN; Rojas-Corona RR; Emralino AB; Jimenez-Joseph D; Sherman ME
Acta Cytol; 1994; 38(6):945-52. PubMed ID: 7992584
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of pleural fluid data in patients with malignant effusion.
Bielsa S; Salud A; Martínez M; Esquerda A; Martín A; Rodríguez-Panadero F; Porcel JM
Eur J Intern Med; 2008 Jul; 19(5):334-9. PubMed ID: 18549935
[TBL] [Abstract][Full Text] [Related]
34. Intraoperative pleural lavage: is it a valid prognostic factor in lung cancer?
Vicidomini G; Santini M; Fiorello A; Parascandolo V; Calabrò B; Pastore V
Ann Thorac Surg; 2005 Jan; 79(1):254-7; discussion 254-7. PubMed ID: 15620952
[TBL] [Abstract][Full Text] [Related]
35. Pleural lavage cytology before and after lung resection in non-small cell lung cancer patients.
Enatsu S; Yoshida J; Yokose T; Nishimura M; Nishiwaki Y; Shirakusa T; Nagai K
Ann Thorac Surg; 2006 Jan; 81(1):298-304. PubMed ID: 16368385
[TBL] [Abstract][Full Text] [Related]
36. [Clinical evaluation of the combination treatment of intrapleural or intraperitoneal administration of lentinan and OK-432 for malignant effusion].
Yoshino S; Yoshida S; Maeda N; Maeda Y; Maeda K; Hazama S; Oka M
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2798-800. PubMed ID: 21224717
[TBL] [Abstract][Full Text] [Related]
37. [Negative pleural cytology after intrapleural perfusion hyperthermo-chemotherapy for malignant pleural effusion].
Yagi T; Ueda K; Kaneda Y; Sakano H; Tanaka T; Matsuoka T; Sudo M; Hayashi M; Hamano K
Kyobu Geka; 2004 Feb; 57(2):107-10. PubMed ID: 14978902
[TBL] [Abstract][Full Text] [Related]
38. Pleural effusion in breast cancer: influence upon clinical course and survival.
Singer TS; Sulkes A; Biran S
Chemioterapia; 1986 Feb; 5(1):66-9. PubMed ID: 3955787
[TBL] [Abstract][Full Text] [Related]
39. Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors.
Nisticò C; Cuppone F; Bria E; Fornier M; Giannarelli D; Mottolese M; Novelli F; Natoli G; Cognetti F; Terzoli E
Anticancer Drugs; 2006 Nov; 17(10):1193-200. PubMed ID: 17075319
[TBL] [Abstract][Full Text] [Related]
40. Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: Treatment of Th1 dysfunction in the ascites microenvironment.
Yamaguchi Y; Ohshita A; Kawabuchi Y; Hihara J; Miyahara E; Noma K; Toge T
Int J Oncol; 2004 Apr; 24(4):959-66. PubMed ID: 15010836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
